Session » Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2757

A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing

9:00AM-11:00AM: Abstract Number: 2762

A Longer or Bilateral Temporal Artery Biopsy (TAB) Is More Likely to Yield a Positive Result for Giant Cell Arteritis (GCA) in the Veterans Health Administration (VHA) Database Cohort

9:00AM-11:00AM: Abstract Number: 2756

A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial

9:00AM-11:00AM: Abstract Number: 2769

A Single Center Experience of Temporal Artery Biopsies Performed in 30 African American Patients

9:00AM-11:00AM: Abstract Number: 2749

Clinical and Anatomical Correlation in Patients with Polymyalgia Rheumatica By 18F-FDG PET/TC. Study of 75 Patients from a Single Referral Center

9:00AM-11:00AM: Abstract Number: 2745

Clinical and Serological Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab or Abatacept As Steroid-Sparing Agents

9:00AM-11:00AM: Abstract Number: 2760

Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice

9:00AM-11:00AM: Abstract Number: 2768

Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study

9:00AM-11:00AM: Abstract Number: 2754

Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients

9:00AM-11:00AM: Abstract Number: 2771

Current Practice of Cardiovascular Risk Assessment in Giant Cell Arteritis: A Single Center Study

9:00AM-11:00AM: Abstract Number: 2773

Diagnostic and Therapeutic Management of a Suspected Case of GCA: An Opinion Survey

9:00AM-11:00AM: Abstract Number: 2777

Dynamics in Peripheral Blood Cell Counts in Giant Cell Arteritis before Treatment, during Treatment and in Treatment-Free Remission

9:00AM-11:00AM: Abstract Number: 2759

Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 2751

Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2783

EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases

9:00AM-11:00AM: Abstract Number: 2753

Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2748

Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT

9:00AM-11:00AM: Abstract Number: 2744

Giant-Cell Arteritis: Is Glucocorticoid-Sparing Treatment Still Relevant? a Retrospective Study

9:00AM-11:00AM: Abstract Number: 2767

Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 2778

High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 2761

High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort

9:00AM-11:00AM: Abstract Number: 2772

Incidence of Cardiovascular Events in Giant Cell Arteritis: A Matched-Control Study

9:00AM-11:00AM: Abstract Number: 2764

Incidence, Characteristics and Management of Giant Cell Arteritis in France: A Study Based on National Health Insurance Claims Data

9:00AM-11:00AM: Abstract Number: 2780

Insufficient Use of Corticosteroids Results in Higher Relapse in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 2776

Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2782

Is It Necessary to Hold Anticoagulation Prior to Temporal Artery Biopsy?

9:00AM-11:00AM: Abstract Number: 2747

Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival

9:00AM-11:00AM: Abstract Number: 2781

Long Term Follow-up Results of Takayasu Arteritis Cohort: A Tertiary-Single Center Study

9:00AM-11:00AM: Abstract Number: 2779

Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 2784

Multi Modal Imaging Algorithm to Improve the Accuracy for the Diagnosis of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2775

Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2766

Seasonal Variation in Incidence of Giant Cell Arteritis: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 2770

The Effect of Metabolic Syndrome on Giant Cell Arteritis Treatment

9:00AM-11:00AM: Abstract Number: 2765

Thyroid Artery Involvement Detected By Colour-Doppler Ultrasonography in an Incipient, Single Centre Giant Cell Arteritis Cohort

9:00AM-11:00AM: Abstract Number: 2752

Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice

9:00AM-11:00AM: Abstract Number: 2758

Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study

9:00AM-11:00AM: Abstract Number: 2746

Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study

9:00AM-11:00AM: Abstract Number: 2774

Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice

9:00AM-11:00AM: Abstract Number: 2750

Utility of Methotrexate in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2763

Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2755

Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis

« View all sessions from this meeting